|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Venous thrombosis and prothrombotic factors in inflammatory bowel disease显示文摘Patients with inflammatory bowel disease(IBD)may have an increased risk of venous thrombosis(VTE).PubMed,ISI Web of Knowledge and Scopus were searched to identify studies investigating the risk of VTE and the prevalence of acquired and genetic VTE risk factors and prothrombotic abnormalities in IBD.Overall,IBD patients have a two-to fourfold increased risk of VTE compared with healthy controls,with an overall incidence rate of 1%-8%.The majority of studies did not show significant differences in the risk of VTE between Crohn’s disease and ulcerative colitis.Several acquired factors are responsible for the increased risk of VTEin IBD:inflammatory activity,hospitalisation,surgery,pregnancy,disease phenotype(e.g.,fistulising disease,colonic involvement and extensive involvement)and drug therapy(mainly steroids).There is also convincing evidence from basic science and from clinical and epidemiological studies that IBD is associated with several prothrombotic abnormalities,including initiation of the coagulation system,downregulation of natural anticoagulant mechanisms,impairment of fibrinolysis,increased platelet count and reactivity and dysfunction of the endothelium.Classical genetic alterations are not generally found more often in IBD patients than in nonIBD patients,suggesting that genetics does not explain the greater risk of VTE in these patients.IBD VTE may have clinical specificities,namely an earlier first episode of VTE in life,high recurrence rate,decreased efficacy of some drugs in preventing further episodes and poor prognosis.Clinicians should be aware of these risks,and adequate prophylactic actions should be taken in patients who have disease activity,are hospitalised,are submitted to surgery or are undergoing treatment. | Fernando Magro Jo?o-Bruno Soares Dália Fernandes | 2014 | World Journal of Gastroenterology2014，20，17： | 27 |
| 2 | Nocardia infections among immunomodulated inflammatory bowel disease patients:A review显示文摘Human nocardiosis,caused by Nocardia spp.,an ubiquitous soil-borne bacteria,is a rare granulomatous disease close related to immune dysfunctions.Clinically can occur as an acute life-threatening disease,with lung,brain and skin being commonly affected.The infection was classically diagnosed in HIV infected persons,organ transplanted recipients and long term corticosteroid treated patients.Currently the widespread use of immunomodulators and immunossupressors in the treatment of inflammatory diseases changed this scenario.Our purpose is to review all published cases of nocardiosis in immunomodulated patients due to inflammatory diseases and describe clinical and laboratory findings.We reviewed the literature concerning human cases of nocardiosis published between 1980 and 2014 in peer reviewed journals.Eleven cases of nocardiosis associated with anti-tumor necrosis factor(TNF) prescription(9 related with infliximab and 2 with adalimumab) were identified; 7 patients had inflammatory bowel disease(IBD),4 had rheumatological conditions; nocardia infection presented as cutaneous involvement in 3 patients,lung disease in 4 patients,hepatic in one and disseminated disease in 3 patients.From the 10 cases described in IBD patients 7 were associated with anti-TNF and 3 with steroids and azathioprine.In conclusion,nocardiosis requires high levels of clinical suspicion and experience of laboratory staff,in order to establish a timely diagnosis and by doing so avoid worst outcomes.Treatment for long periods tailored by the susceptibility of the isolated species whenever possible is essential.The safety of restarting immunomodulators or anti-TNF after the disease or the value of prophylaxis with cotrimoxazole is still debated. | Candida Abreu Nuno Rocha-Pereira António Sarmento Fernando Magro | 2015 | World Journal of Gastroenterology2015，21，21： | 18 |
| 3 | Biliary complications after liver transplantation:current perspectives and future strategies显示文摘Importance:Liver transplantation(LT)is a life-saving therapy for patients with end-stage liver disease and with acute liver failure,and it is associated with excellent outcomes and survival rates at 1 and 5 years.The incidence of biliary complications(BCs)after LT is reported to range from 5%to 20%,most of them occurring in the first three months,although they can occur also several years after transplantation.Objective:The aim of this review is to summarize the available evidences on pathophysiology,risk factors,diagnosis and therapeutic management of BCs after LT.Evidence Review:a literature review was performed of papers on this topic focusing on risk factors,classifications,diagnosis and treatment Findings:Principal risk factors include surgical techniques and donor’s characteristics for biliary leakage and anastomotic biliary strictures and vascular alterations for non-anastomotic biliary strictures.MRCP is the gold standard both for intra-and extrahepatic BCs,while invasive cholangiography should be restricted for therapeutic uses or when MRCP is equivocal.About treatment,endoscopic techniques are the first line of treatment with success rates of 70-100%.The combined success rate of ERCP and PTBD overcome 90%of cases.Biliary leaks often resolve spontaneously,or with the positioning of a stent in ERCP for major bile leaks Conclusions and Relevance:BCs influence morbidity and mortality after LT,therefore further evidences are needed to identify novel possible risk factors,to understand if an immunological status that could lead to their development exists and to compare the effectiveness of innovative surgical and machine perfusion techniques. | Bianca Magro Matteo Tacelli Alessandra Mazzola Filomena Conti Ciro Celsa | 2021 | Hepatobiliary Surgery and Nutrition2021，10，1： | 12 |
| 4 | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis显示文摘 | Axel Dignass Rami Eliakim Fernando Magro Christian Maaser Yehuda Chowers Karel Geboes Gerassimos Mantzaris Walter Reinisch Jean-Frederic Colombel Severine Vermeire Simon Travis James O. Lindsay Gert Van Assche | 2012 | Journal of Crohn’s and Colitis2012，，10： | 12 |
| 5 | Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy:A single center report of 8 cases显示文摘This article describes cases of anti-tumor necrosis factor(TNF)-α-induced autoimmune hepatitis and evaluates the outcome of these patients in relation to their immunosuppressive strategy. A retrospective analysis of medical records was performed in our center, in order to detect cases of autoimmune hepatitis(AIH) associated with anti-TNF biologic agents. We describe and analyze eight cases of AIH following anti-TNF therapy, 7 with infliximab and 1 with adalimumab. A distinction should be made between induction of autoimmunity and clinically evident autoimmune disease. Liver biopsy is useful in detecting the role of the TNF-α antagonist in the development of AIH. The lack of relapse after discontinuing immunosuppressive therapy favors, as in this case series, an immune-mediated drug reaction as most patients with AIH have a relapse after treatment is suspended. Although AIH related to anti-TNF therapy is rare, a baseline immunological panel along with liver function tests should be performed in all patients with autoimmune disease before starting biologics. | Susana Rodrigues Susana Lopes Fernando Magro Hélder Cardoso Ana Maria Horta e Vale Margarida Marques Eva Mariz Miguel Bernardes Joanne Lopes Fátima Carneiro Guilherme Macedo | 2015 | World Journal of Gastroenterology2015，21，24： | 9 |
| 6 | Posterior partially edentulous jaws, planning a rehabilitation with dental implants显示文摘AIM: To discuss important characteristics of the useof dental implants in posterior quadrants and the rehabilitation planning. METHODS: An electronic search of English articles was conducted on MEDLINE(PubM ed) from 1990 up to the period of March 2014. The key terms were dental implants and posterior jaws, dental implants/treatment planning and posterior maxilla, and dental implants/treatment planning and posterior mandible. No exclusion criteria were used for the initial search. Clinical trials, randomized and non randomized studies, classical and comparative studies, multicenter studies, in vitro and in vivo studies, case reports, longitudinal studies and reviews of the literature were included in this review. RESULTS: One hundred and fifty-two articles met the inclusion criteria of treatment planning of dental implants in posterior jaw and were read in their entirety. The selected articles were categorized with respect to their context on space for restoration, anatomic considerations(bone quantity and density), radiographic techniques, implant selection(number, position, diameter and surface), tilted and pterygoid implants, short implants, occlusal considerations, and success rates of implants placed in the posterior region. The results derived from the review process were described under several different topic headings to give readers a clear overview of the literature. In general, it was observed that the use of dental implants in posterior region requires a careful treatment plan. It is important that the practitioner has knowledge about the theme to evaluate the treatment parameters. CONCLUSION: The use of implants to restore the posterior arch presents many challenges and requires a detailed treatment planning. | Douglas R Monteiro Emily V F Silva Eduardo P Pellizzer Osvaldo Magro Filho Marcelo C Goiato | 2015 | World Journal of Clinical Cases2015，3，1： | 6 |
| 7 | Clinical prognostic factors for disabling Crohn's disease: A systematic review and meta-analysis显示文摘AIM: To identify demographic and clinical factors asso-ciated with disabling Crohn's disease (CD). METHODS: A systematic review and meta-analysisof observational studies, focusing on the factors that can predict the prognosis of different outcomes of CD was undertaken. PubMed, ISI Web of Knowledge and Scopus were searched to identify studies investigat-ing the above mentioned factors in adult patients with CD. Studies were eligible for inclusion if they describe prognostic factors in CD, with inclusion and exclusion criteria defined as follows. Studies with adult patients and CD, written in English and studying association between clinical factors and at least one prognosis out-come were included. Meta-analysis of effects was un-dertaken for the disabling disease outcome, using odds ratio (OR) to assess the effect of the different factors in the outcome. The statistical method used was Mantel-Haenszel for fixed effects. The 16-item quality assess-ment tool (QATSDD) was used to assess the quality of the studies (range: 0-42). RESULTS: Of the 913 papers initially selected, sixty studies were reviewed and three were included in the systematic review and meta-analysis. The global QA-TSDD scores of papers were 18, 21 and 22. Of a total of 1961 patients enrolled, 1332 (78%) were classified with disabling disease five years after diagnosis. In two studies, age at diagnosis was a factor associated with disabling disease five years after diagnosis. Individu-als under 40 years old had a higher risk of developing disabling disease. In two studies, patients who were treated with corticosteroids on the first flare developed disabling disease five years after diagnosis. Further, perianal disease was found to be relevant in all of the studies at two and five years after diagnosis. Finally, one study showed localization as a factor associated with disabling disease five years after diagnosis, with L3 being a higher risk factor. This meta-analysis showed a significantly higher risk of developing disabling dis-ease at five years after initial diagnosis among patients younger than 40 years of age (OR=2.47, 95%CI: 1.74-3.51), with initial steroid treatment for first flare (OR=2.42, 95%CI: 1.87-3.11) and with perianal dis-ease (OR = 2.00, 95%CI: 1.41-2.85).CONCLUSION: Age at diagnosis, perianal disease, ini-tial use of steroids and localization seem to be indepen-dent prognostic factors of disabling disease. | Cláudia Camila Dias Pedro Pereira Rodrigues Altamiro da Costa Pereira Fernando Magro | 2013 | World Journal of Gastroenterology2013，19，24： | 2 |
| 8 | Pyoderma gangrenosum:a review显示文摘 | Crowson AN Jr MCM Magro C | 2003 | J Cutan Pathol2003，30，： | 2 |
| 9 | European consensus on the histopathology of inflammatory bowel disease显示文摘 | F. Magro C. Langner A. Driessen A. Ensari K. Geboes G.J. Mantzaris V. Villanacci G. Becheanu P. Borralho Nunes G. Cathomas W. Fries A. Jouret-Mourin C. Mescoli G. de Petris C.A. Rubio N.A. Shepherd M. Vieth R. Eliakim | 2013 | Journal of Crohn’s and Colitis2013，，： | 2 |
| 10 | High C-reactive protein in Crohn’s disease patients predicts nonresponse to Infliximab treatment显示文摘 | Fernando Magro Eduardo Rodrigues-Pinto Jo?o Santos-Antunes Filipe Vilas-Boas Susana Lopes Amadeu Nunes Claudia Camila-Dias Guilherme Macedo | 2013 | Journal of Crohn’s and Colitis2013，，： | 2 |
| 11 | Second European evidence-based consensus on the prevention,diagnosis and management of opportunistic infections in inflammatory boweldisease显示文摘 | Rahier JF Magro F Abreu C | 2014 | J Crohns Colitis2014，8，6： | 1 |
| 12 | Early hematopoietic recovery after single unit unrelated cord blood transplantation in adults supported by co-infusion of mobilized stem cells from a third party donor显示文摘 | Magro E Regidor C Cabrera R | 2006 | Haematologica2006，91，5： | 1 |
| 13 | The interstitial granuloma- tous drug reaction: a distinctive clinical and pathological entity 显示文摘 | Magro CM Crowson AN Shapiro BL | 1998 | J Cutan Pathol1998，25，2： | 1 |
| 14 | Low grade periductal stromal sarcoma with marked sclero-elastosis 显示文摘 | Caltabiano R Magro G Vecchio GM | 2011 | Pathology2011，43，5： | 1 |
| 15 | Surgical treat of complete rectal prolapse experience at colon and rectal surgery service显示文摘 | Martinez Hernandez Magro P | 2003 | Rev Gastroenterol Mex2003，68，3： | 1 |
| 16 | Oxalic acid, cell wall - degrading enzymes and pH in pathogenesis and their significance in the virulence of two Sclerotinia sclerotiorum isolates on sunflower 显示文摘 | Marciano P Lenna P D Magro P | 1983 | Physiol Plant Pathol1983，22，： | 1 |
| 17 | A Causal role for parvovirus B19 infection in adult dermatomyositis and other autoimmune syndromes显示文摘 | CROWSON AN MAGRO CM DAWOOD MR | 2000 | J Cutan Pathol2000，27，： | 1 |
| 18 | The spectrum of cutaneous lesions in rheumatoid arthritis: a clinical and pathological study of 43 patients显示文摘 | Magro CM Crowson AN | 2003 | J Cutan Pathol2003，30，1： | 1 |
| 19 | Lipomatous angiomyo- fibroblastoma of the vulva: diagnostic and histogenetic considera- tions显示文摘 | Magro G Salvatorelli L Angelico G | 2014 | Pathologica2014，106，4： | 1 |
| 20 | Regulation of beta-cell function by RNA-binding proteins 显示文摘 | Magro M G Solimena M | 2013 | Molecular metabolism2013，2，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员